Biocon Q4 results: Net profit surges 153% at Rs 344 crore

Biocon on Thursday reported a 153% surge in net profit for the fourth quarter ended March to Rs 344 crore, while consolidated total revenue for Q4 was Rs 4,454 crore, a growth of 12% over last year, the company said in a press release.

Group core EBITDA for the quarter stood at Rs 1,363 crore, up 16% from last year, with a core operating margin of 31%. EBITDA for the quarter stood at Rs 1,115 crore, up 16% with a margin of 25%.

Speaking on the group’s performance, Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said: “The launch of Liraglutide in the UK market heralded our entry into the GLP-1 therapy segment. Our biosimilars continue to build impressive shares in global markets with four biosimilars recording sales of $200 million each in FY25.”


“This quarter marked the expansion of Syngene’s biologics manufacturing footprint through an acquisition of a state-of-the-art manufacturing facility in the US,” she added.

“FY25 has been a year of consolidation and transition. We are now on a path of accelerating growth with a commitment to innovation, digital augmentation and operational excellence.”

The company’s Board has approved raising of funds up to Rs 4,500 crore, through the issue of securities via qualified institutional placements, rights issue, or other permissible routes.

The Board of Directors has recommended a final dividend of Rs 0.50 per share at the rate of 10% of the face value of the share, for the financial year ended March 31.

For the year ended FY25, consolidated total revenue was at Rs 16,470 crore, up 5% YoY. Total revenue grew 8% YoY on a like-for-like basis, after adjusting for revenues and divestment gain from BFI and stake dilution gain in Bicara. Net profit for FY25 was Rs 1,013 crore, almost flat at last fiscal's Rs 1,022 crore, which included Bicara gain & income from part divestment of BFI business by Biocon Biologics.

On a like-for-like basis, net profit grew 30% after adjusting for the revenues from BFI, BFI divestment gain and dilution/fair valuation gain in Bicara.

The generics business delivered a 46% YoY and a 53% sequential growth in Q4, concluding FY25 with an overall 8% growth over the previous year.

“The performance was primarily driven by contributions from new product launches, notably Lenalidomide and Dasatinib in the US, supported by modest growth in our API business,” said Siddharth Mittal, CEO & Managing Director, Biocon Limited.

“Looking ahead, we remain focused on the strategic expansion of our differentiated GLP-1 portfolio into new markets, which will position us well for growth. In FY26, we also expect to see a recovery in the API business, aided by our cost improvement initiatives, enhancement of operational efficiencies, and new capacities coming on-stream,” he added. End